Medical Journals

Selective Activation of Nuclear Phospholipase D-1 by G Protein-coupled Receptor Agonists in Vascular Smooth Muscle Cells.

Authors:
  • Gayral Stéphanie
  • Déléris Paul
  • Laulagnier Karine
  • Laffargue Muriel
  • Salles Jean-Pierre
  • Perret Bertrand
  • Record Michel
  • Breton-Douillon Monique

From: Département Lipoprotéines and Médiateurs Lipidiques, CPTP, INSERM Unité 563, Bâtiment C, CHU Purpan, BP 3028, 31024 Toulouse Cedex 3, France.

Circulation research

  • Publish Date: Jul 2006
  • ISSN: 1524-4571
  • Volume: 99
  • Issue: 2
  • Pages: 132-9
  • Medium: Internet
  • Language: English
  • Citation (JAMA): Gayral Stéphanie, Déléris Paul, Laulagnier Karine, et al. Selective Activation of Nuclear Phospholipase D-1 by G Protein-coupled Receptor Agonists in Vascular Smooth Muscle Cells.. Circ. Res. Jul 2006;99:132-9

Abstract

Recent studies highlight the existence of an autonomous nuclear lipid metabolism related to cellular proliferation. However, the importance of nuclear phosphatidylcholine (PC) metabolism is poorly understood. Therefore, we were interested in nuclear PCs as a source of second messengers and, particularly, nuclear phospholipase D (PLD) identification in membrane-free nuclei isolated from pig aorta vascular smooth muscle cells (VSMCs). Using immunoblot experiment, in vitro PLD assay with fluorescent substrate and confocal microscopy analysis, we demonstrated that only PLD1 is expressed in VSMC nucleus, whereas PLD1 and PLD2 are present in VSMC. Inhibition of RhoA and protein kinase Czeta (PKCzeta) by C3-exoenzyme and PKCzeta pseudosubstrate inhibitor, respectively, conducted a decrease of phosphatidylethanol production. On the other hand, treatment of intact VSMCs, but not nuclei, with phosphoinositide 3-kinase (PI3K) inhibitors prevented partially nuclear PLD1 activity, indicating for the first time that PI3K may have a role in nuclear PLD regulation. In addition, lysophosphatidic acid (LPA) or angiotensin II treatment of VSMCs resulted in an increase of intranuclear PLD activity, whereas platelet-derived growth factor and epidermal growth factor have no significant effect. Moreover, pertussis toxin induced a decrease of LPA-stimulated nuclear PLD1 activity, suggesting that heterotrimeric G(i)/G(0) protein involvement in intranuclear PLD1 regulation. We also show that LPA-induced nuclear PLD1 activation implied PI3K/PKCzeta pathway activation and PKCzeta nuclear translocation as well as nuclear RhoA activation. Thus, the characterization of an endogenous PLD1 that could regulate PC metabolism inside VSMC nucleus provides a new role for this enzyme in control of vascular fibroproliferative disorders.

Mesh Headings (Keywords): 1-Phosphatidylinositol 3-Kinase, Angiotensin II, Animals, Aorta, Cells, Cultured, Enzyme Activation, Humans, Lysophospholipids, Muscle, Smooth, Vascular, Myocytes, Smooth Muscle, Nuclear Proteins, Pertussis Toxin, Phosphatidylcholines, Phospholipase D, Receptors, G-Protein-Coupled, Swine


Check for Full Text / PubMed Unique Identifier (PMID): 16778131


This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.

Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.

The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.


Advertisements

About | Privacy Policy | Business Solutions | Advertise | Contact | Add Healia to your site

©2012. Healia / Meredith Corporation  

Use of this site constitutes acceptance of our Terms of Service and Privacy Policy. All content on this Web site, including medical opinion and any other health-related information, is for informational purposes only and should not be used for a specific diagnosis or individual treatment plan for any situation. Use of this site and the information contained herein does not create a doctor-patient relationship. Always seek the direct advice of your doctor in connection with any questions or issues you may have regarding your own health or the health of others.